Technical Analysis for BMEA - Biomea Fusion, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 7.03% | |
Bollinger Band Squeeze | Range Contraction | 7.03% | |
Earnings Movers | Other | 7.03% |
Alert | Time |
---|---|
Possible Pocket Pivot | about 11 hours ago |
60 Minute Opening Range Breakout | about 14 hours ago |
Rose Above Previous Day's High | about 17 hours ago |
Rose Above Upper Bollinger Band | about 17 hours ago |
Up 5% | about 17 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
T
TraderMike about 1 year ago
I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji). These little biotechs are always interesting after having a big pop based on some good/promising news. The standard plan seems to be to immediately issue a secondary offering -- which BMEA did. So now I'm looking for it to climb back above that offering price of $30 and retest the March high.
View full discussion...
Indicator | Value |
---|---|
52 Week High | 43.64 |
52 Week Low | 8.125 |
Average Volume | 1,062,500 |
200-Day Moving Average | 14.37 |
50-Day Moving Average | 13.32 |
20-Day Moving Average | 11.38 |
10-Day Moving Average | 11.88 |
Average True Range | 0.96 |
RSI (14) | 57.98 |
ADX | 19.13 |
+DI | 26.58 |
-DI | 19.54 |
Chandelier Exit (Long, 3 ATRs) | 10.45 |
Chandelier Exit (Short, 3 ATRs) | 13.10 |
Upper Bollinger Bands | 12.84 |
Lower Bollinger Band | 9.92 |
Percent B (%b) | 1.14 |
BandWidth | 25.67 |
MACD Line | -0.26 |
MACD Signal Line | -0.57 |
MACD Histogram | 0.3005 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 14.46 | ||||
Resistance 3 (R3) | 14.36 | 13.84 | 14.26 | ||
Resistance 2 (R2) | 13.84 | 13.53 | 13.90 | 14.19 | |
Resistance 1 (R1) | 13.54 | 13.34 | 13.69 | 13.65 | 14.12 |
Pivot Point | 13.03 | 13.03 | 13.10 | 13.08 | 13.03 |
Support 1 (S1) | 12.73 | 12.72 | 12.88 | 12.83 | 12.36 |
Support 2 (S2) | 12.21 | 12.52 | 12.27 | 12.29 | |
Support 3 (S3) | 11.91 | 12.21 | 12.22 | ||
Support 4 (S4) | 12.02 |